These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
675 related articles for article (PubMed ID: 22449781)
1. Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling. Wang HY; Wang RF Adv Immunol; 2012; 114():151-76. PubMed ID: 22449781 [TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy: sipuleucel-T and beyond. Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608 [TBL] [Abstract][Full Text] [Related]
3. Engineering Dendritic-Cell-Based Vaccines and PD-1 Blockade in Self-Assembled Peptide Nanofibrous Hydrogel to Amplify Antitumor T-Cell Immunity. Yang P; Song H; Qin Y; Huang P; Zhang C; Kong D; Wang W Nano Lett; 2018 Jul; 18(7):4377-4385. PubMed ID: 29932335 [TBL] [Abstract][Full Text] [Related]
4. Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine. Belnoue E; Mayol JF; Carboni S; Di Berardino Besson W; Dupuychaffray E; Nelde A; Stevanovic S; Santiago-Raber ML; Walker PR; Derouazi M JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31013258 [TBL] [Abstract][Full Text] [Related]
5. Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4+ and CD8+ T Cell-Mediated Antitumor Immunity. Derouazi M; Di Berardino-Besson W; Belnoue E; Hoepner S; Walther R; Benkhoucha M; Teta P; Dufour Y; Yacoub Maroun C; Salazar AM; Martinvalet D; Dietrich PY; Walker PR Cancer Res; 2015 Aug; 75(15):3020-31. PubMed ID: 26116496 [TBL] [Abstract][Full Text] [Related]
6. Current status and future prospects of peptide-based cancer vaccines. Wada S; Yada E; Ohtake J; Fujimoto Y; Uchiyama H; Yoshida S; Sasada T Immunotherapy; 2016 Nov; 8(11):1321-1333. PubMed ID: 27993087 [TBL] [Abstract][Full Text] [Related]
7. Mechanistic insights into the efficacy of cell penetrating peptide-based cancer vaccines. Grau M; Walker PR; Derouazi M Cell Mol Life Sci; 2018 Aug; 75(16):2887-2896. PubMed ID: 29508006 [TBL] [Abstract][Full Text] [Related]
8. Incorporation of the Tat cell-penetrating peptide into nanofibers improves the respective antitumor immune response. Mohammadi M; Dehghani P; Mohseninia A; Roozbehani M; Hemphill A; Hesamizadeh K J Cell Physiol; 2021 Feb; 236(2):1401-1417. PubMed ID: 32686113 [TBL] [Abstract][Full Text] [Related]
9. Intracellular delivery of tumor antigenic peptides in biodegradable-polymer adjuvant for enhancing cancer immunotherapy. Li H; Ma W Curr Med Chem; 2014; 21(21):2357-66. PubMed ID: 25030301 [TBL] [Abstract][Full Text] [Related]
10. Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants. Belnoue E; Di Berardino-Besson W; Gaertner H; Carboni S; Dunand-Sauthier I; Cerini F; Suso-Inderberg EM; Wälchli S; König S; Salazar AM; Hartley O; Dietrich PY; Walker PR; Derouazi M Mol Ther; 2016 Sep; 24(9):1675-85. PubMed ID: 27377043 [TBL] [Abstract][Full Text] [Related]
13. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses. Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391 [TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? Parmiani G; Castelli C; Dalerba P; Mortarini R; Rivoltini L; Marincola FM; Anichini A J Natl Cancer Inst; 2002 Jun; 94(11):805-18. PubMed ID: 12048268 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells. Lee JM; Shin KS; Koh CH; Song B; Jeon I; Park MH; Kim BS; Chung Y; Kang CY Cancer Lett; 2021 Nov; 520():38-47. PubMed ID: 34224797 [TBL] [Abstract][Full Text] [Related]
16. Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability. Moynihan KD; Holden RL; Mehta NK; Wang C; Karver MR; Dinter J; Liang S; Abraham W; Melo MB; Zhang AQ; Li N; Gall SL; Pentelute BL; Irvine DJ Cancer Immunol Res; 2018 Sep; 6(9):1025-1038. PubMed ID: 29915023 [TBL] [Abstract][Full Text] [Related]
19. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens. Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834 [TBL] [Abstract][Full Text] [Related]
20. The present status and future prospects of peptide-based cancer vaccines. Hirayama M; Nishimura Y Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]